Business Wire

Thales Unveils New Secrets Management Solution to Help Reduce Risks and Improve DevOps and Cloud Security

24.4.2023 16:00:00 EEST | Business Wire | Press release

Share

Thales, the leading global technology and security provider, today announced the introduction of a new secrets management solution as part of its CipherTrust Data Security platform which unifies the discovery, classification, protection, and control of sensitive data across cloud, on-premises and hybrid environments. Thales’s new secrets management solution, powered by Akeyless’ Vault Platform, enables customers to manage and secure DevOps and cloud workloads’ secrets. The new capability enhances the capabilities of the CipherTrust Data Security platform to help security and governance teams reduce risks by streamlining security processes across their operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230424005088/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

@Thales

Thales’ new secrets management solution helps ensure that only authorized workloads and applications can access their passwords, API keys, and certificates, protecting them from unauthorized access, theft, or misuse. The process of secrets management typically involves generating and storing secrets securely, controlling access, and monitoring to alert when there is a suspicion of a breach and associated details.

Todd Moore, vice president of data security products at Thales: "Combining secrets management with key management is like having a fortified vault for all your valuable assets. We are pleased to meet our customers growing business needs by offering a single data security platform that can simplify the management of all their sensitive data, improve security and compliance, foster development collaboration, and scale their security infrastructure."

The addition of secrets management enables the CipherTrust Data Security Platform to solve several pain points for customers related to the storing and managing of secrets securely, including:

  • Mitigating the risk of data breaches: By providing secure storage and access control to sensitive data such as passwords, API keys, and certificates, which are valuable targets for attackers, it mitigates the risk of data breaches.
  • Simplifying the management of secrets: In many organizations, passwords and certificates are managed manually or with ad-hoc processes, which are time-consuming and error-prone, especially in large or complex environments.
  • Ensuring compliance with regulations and standards: Some industries and regions require compliance with specific regulations and standards for data security which could be very complex to navigate.
  • Enabling collaboration: Multiple teams or individuals who need access to secrets now have a centralized and secure way to collaborate on projects.

With support for secrets management, the CipherTrust Data Security Platform further simplifies customers' processes by allowing centralized management of secrets and keys and scaling up to encryption solutions and other data security use cases.

Shai Onn, President & Co-founder at Akeyless : “As enterprises increasingly adopt DevOps practices, Automation, containerization, and more cloud technologies, they face a new rising threat in the form of Secrets Sprawl, where credentials, certificates and keys of all forms are being found in large quantities within source code, configuration files, and DevOps automation platforms. In recent years, Akeyless has pioneered the SaaS based Secrets Management market, becoming the perfect choice for reputable enterprises globally, making it a natural partner for Thales. With Akeyless Vault Platform’s secrets management solution, Thales can offer a more holistic and cohesive platform for its customers enabling them to centralize and streamline their DevOps Security efforts, Cloud IAM initiatives and Encryption solutions projects.

For a demo, visit Thales’ booth #N-5369 and Akeyless.io’s booth #S-1861 at RSA 2023 (April 24 – 27 in San Francisco, USA) or learn more here.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum technologies – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organizations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfill their critical role, consideration for the individual being the driving force behind all decisions.

Thales has 77,0001 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion.

PLEASE VISIT
Thales Group
Cloud Protection & Licensing Solutions | Thales Group
Cybersecurity Solutions | Thales Group

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS CONTACT
Thales, Media Relations
Security & Cybersecurity
Marion Bonnet
+33 (0)6 60 38 48 92
marion.bonnet@thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye